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INACTIVATION OF VACUOLATING VIRUS (SV 40)
BY BETA-PROPIOLACTONE
I. EVALUATION IN TISSUE CULTURE
H A J I M E HAYASHI, Ph.D.

AND GERALD A. LOGRIPPO, M.D.

SIMIAN VIRUS 40 (SV 40) has been of great concern to virologists and clinicians
since Sweet et al.'" reported in 1960 the vacuolating virus from cell cultures of
rhesus and of cynomolgus monkey kidney. It was shown as a viable contaminant
of poliomyelitis and adenovirus vaccines, cultured from rhesus and cynomolgus kidney
cells."'" SV 40 has been called "vacuolating virus" by Sweet et al." because of its
prominent cytoplasmic vacuolation, seen in infected kidney cultures of Cercopethecus
aethiops (African grivet monkey) and is considered unique among simian viruses.
In addition, it was reported that SV 40 showed cytopathic effects (CPE) on primary
cultures of several human tissues."
It is of growing interest among virologists that SV 40 is oncogenic as shown
by Eddy and associates.' They reported the appearance of undifferentiated sarcomas
in subcutaneous tissues, kidneys and lungs of hamsters which had been inoculated
within three days after birth with the cell extracts of frozen and ground primary
cell cultures of rhesus monkey kidney. Such tumors appeared within six to nine
months after inoculation. In subsequent publications^'^ Eddy and coworkers identified
SV 40 in the kidney extract as responsible for tumor formation in hamsters. Furthermore, Girardi et al.^ also showed that SV 40 induced single or multiple fibrosarcomas
at the site of injection which were histologically of varying degrees of malignancy
in hamsters inoculated at birth. Other oncogenic viruses are now recognized and
Melnick'^ has proposed the name "Pa-po-va" for the oncogenic group which includes
the papilloma virus (in rabbit and human warts), polyoma virus and vacuolating
virus (SV 40). This new group is classified on their similarities in virus properties
such as size, stability, D N A nature, etc. as well as their oncogenicity.
Although these findings should be of concern to the clinician, they should not
be alarming, as no clinical signs and symptoms in man have been reported from
SV 40 exposure. Morris et al." mentioned that none of 35 adult volunteers showed
any clinical manifestations after SV 40 was administered by the respiratory route.
•Department of Laboratories
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SV 40 was recovered from throat specimens in three of the volunteers on seven to
eleven days after exposure. In addition virus neutralizing antibody against this agent
appeared in the serum in 22 of 35 volunteers. Melnick and Stinebaugh'" also reported
experiments on 3- to 6-month-old infants who were fed SV 40 found in the poliomyelitis oral vaccine. They showed that some of the infants excreted vacuolating
virus for four weeks and that the vacuolating virus seemed to interfere in some
degree with the multiphcation of the poliomyelitis virus in the gastrointestinal tract,
as SV 40 carriers excreted less polio virus for shorter intervals of time than did
those infants who did not become infected by the SV 40.
Since the SV 40 is more resistant to formalin treatment than is the poliomyelitis
and adenoviruses in vaccine production,"'" new methods for SV 40 inactivation are
being sought. This is essential since SV 40 is considered a potential hazard. The
purpose of this presentation is to appraise the usefulness of beta-propiolactone (BPL) in
the inactivation of SV 40 and the value of this drug in vaccine production problems.
The usefulness of BPL in cold sterilization of biological materials' '"'" '^ and in the
preparadon of inactivated virus vaccines"''"'" has been reported.
MATERIALS AND METHODS

Cell Cultures
A continuous kidney cell line of Cercopithecus aethiops, African green monkey
(BS-C-1)' was obtained from Mrs. H. E. Hopps, Division of Biologies Standards, National
Institutes of Health, Bethesda, Md. Growth medium for these cells consists of M199,'5
0.1 per cent yeastolate (Difco), 20 per cent fetal bovine serum and antibiotics (100 tig
of streptomycin and 100 units of penicillin per ml). Maintenance medium consists of
MI99 with the same concentradon of antibiotics. Tube and bottle cultures were prepared
by the trypsinization procedure.
Virus
Simian virus 40 (SV 40) strain A 426-RN-2 supplied by Dr. B. E. Eddy, Division
of Biologies Standards, NIH, was serially propagated on BS-C-I cells in this laboratory.
The TCID50 of this agent in suspension was at least lO"'-^ per ml and all experiments
showed this virus titer or higher. In addition, virus infected cells were employed to
test the concentration of BPL necessary to penetrate and inactivate SV 40 intracellularly.
For this study 100,000 cells per ml were treated while suspended in the original undiluted
tissue cultured virus suspension. This preparation was harvested at the peak phase of CPE.
Beta-propiolactone*

(BPL) solutions

From a 10 per cent I(wt/voI) (Sp. Gr. BPL-1.149)] BPL solution prepared in cold
distilled water, all serial dilutions were made immediately before addition to virus suspension
or virus infected cell suspensions in proportional amounts necessary for final concentrations.
Since BPL hydrolyzes rapidly in water, all solutions must be freshly prepared in cold
distilled water in order to maintain the maximum amount of the lactone form of the drug.'
Conditions for virus inactivation
The principles employed for treating humaii plasma against the hepatitis virus'''"
were used in these studies. Undiluted virus-drug mixtures were made at 4-9°C. by keeping
all materials in ice baths. All mixtures were intermittendy and vigorously shaken for
3-5 minutes, then allowed to stand at 4-9°C. for at least one hour. Such mixtures were
then incubated at 37°C. for two hours for rapid hydrolysis and action of BPL Infected
cell-drug mixtures were similarly treated. Since BPL forms acid products on hydrolysis,
*Betaprone: "Specially purified" brand of beta-propiolactone, available only from Testagar & Co.
Detroit, Michigan.
''
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sterile 1 N. NaOH solution was used for pH adjustments (7.0-7.2) in proportion to the
rate of acids formed. This was readily accomplished by ths phenal red indicator systsm
prssent in tissue culture fluid.
SV 40 infectivity tests
To each BS-C-1 tube culture, 0.2 m.l. of virus-drug or infected cell-drug mixture
was added and incubated at 37°C. in stationary position or on roller drums. Tissue culture
fluid from tubes with nsgative CPE was subcultured twics when indicated. In bulk tssts.
10 ml. (20 per cent of volume treated) of virus-drug or cell-drug mixtures wsre added
to BS-C-1 csUs grown in 32 oz. prsscription botdes. Although CPE for SV 40 was
observed betwesn 3 to 8 days, all test materials were maintained for 14 to 28 days,
dependsnt upon ths degsneration tims for the normal cell cultures in the respective tests.
Parallel controls with normal cell cultures were conducted with equivalent amounts of
the degeneration products formed from 0.35 per cent BPL in maintenance medium. Such
quantities were not deletsrious to the cell cultures.
RESULTS

The efficacy of BPL in inactivating the SV 40 in vitro is evaluated by its
ability to inhibit the CPE on BS-C-1 cells (Figure l a ) . The cells become large.

'Mr

Figure l a
Arrows indicate areas of characteristic CPE from SV 40 infection on BS-C-1 cell cultures (X450)
rounded or elongated and swollen with multiple vacuoles. Disruption of the normal
cell monolayer with detachment of cells from the glass surface is readily observed
in Figures la and lb. This effect becomes apparent in 3-8 days. Figure l b is an
enlarged area of SV 40 infected cells showing the vacuolation in more detail. Normal
cells are shown in Figure 2. They appear as a monolayer sheet of cells in pavementlike arrangement with no detachment from the glass surface.
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Figure l b
Enlargement of areas showing cellular vacuoles indicated by arrows in Figure la (X1935)

If

s

Figure 2
Normal monolayer sheet of BS-C-1 cell cultures {X450)
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Since 17 animal viruses have been inactivated with 0.4 per cent or less concentration of BPL", 0.35 per cent and less was selected for range of inactivation
for the SV 40. Table I shows the preliminary results of varying concentrations of
BPL from 0.35 per cent to 0.125 per cent. The table also shows the concentration
of BPL required to inactivate the virus suspension in undiluted tissue culture fluid.
In addition, the quantity of BPL is shown which is required to penetrate monkey
Table I
Effect of Beta-propiolactone (BPL) on Simian Virus 40 (SV 40)
Cytopathic Effects on BS-C-1 Cells
Percent
BPL concentrations
0.35
0.20
0.10
0.05
0.025
0.0125

SV 40 i n T C f l u i d
suspension

SV 40 infected cell
suspension

0/4*
0/4
4/4
4/4
4/4
4/4

0/4
2/4
4/4
4/4
4/4
4/4

*Numerator indicates numbers of tubes with positive CPE and denominator numbers of tubes tested.

kidney cells laden with intracellular virus suspended in its originally infected tissue
culture fluid. In columns 1 and 2 of Table I , the inactivation concentration lies
between values 0.2 per cent and 0.1 per cent BPL when the virus is in a cell free
tissue culture fluid. However, BPL concentrations between 0.35 per cent and 0.2
per cent are required to penetrate infected cells and achieve the same degree of
virus inactivation.
The data seen in Table I I are the results of two subsequent experiments which
indicate that 0.14 per cent BPL is sufficient to inactivate the virus suspension but
that 0.35 per cent of BPL is the minimum concentration necessary to penetrate the
cells and inactivate SV 40.
Table I I
Effect of Beta-propiolactone on SV 40 (Data from two experiments: tube method)
Cytopathic Effects on BS-C-1 cells
Percent
BPL concentrations
0.35
0.30
0.25
0.20
0.18
0.16
0.14
0.12
0.10

SV 40 i n T C fluid
suspension
NT*
NT
NT
NT
0/8**
0/8**
0/8**
8/8
8/8

*NT: Not tested.
**Indicates negative CPE in three successive cultures.
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suspension
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5/8
8/8
8/8
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NT
NT
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Table I I I is a summary of three experiments in which larger volumes of virusdrug mixtures of infected materials were tested in larger containers with greater
numbers of host cells. Such bulk tests serve to demonstrate trace quantities of virus
which can be manifested only by testing larger samples of infected materials. In

Table I I I
Effect of Beta-propiolactone on SV 40 (Data from three experiments: bulk test)
Percent
BPL concentrations
0.35
0.20
0.18
0.16
0.14

Cytopathic Effects on BS-C-1 cells
SV 40 in TC fluid
Suspension
NT*
0/3**
0/3
0/3
1/3

SV 40 infected cell
Suspension
0/4
NT
NT
NT
NT

*NT: Not tested.
**Numerator indicates numbers of bottles with positive CPE, and denominator numbers of bottles
tested.
the undiluted tissue culture fluid, results indicate that 0.16 per cent BPL concentration is necessary for complete inactivation of SV 40 whereas in the tube method
0.14 per cent was effective; indicating the presence of trace virus quantities not
detectable in the tube test. However, in the infected cell suspension, the effective
concentration of BPL remained 0.35 per cent as indicated in the tube test.
DISCUSSION

One of the reasons for this study was to ascertain whether the concentration
of BPL necessary to inactivate the SV 40 would be less than that necessary to
inactivate the poliomyelitis and adenoviruses in tissue culture suspensions. In previous
publication" it was shown that 0.3 per cent BPL inactivated the poliomyelitis virus
by the tube method but that 0.4 per cent was required to eliminate trace quantities
as shown in the bulk method. The inactivating concentration for adenovirus (Type 3)
was 0.3 per cent by the bulk method. The SV 40 is more susceptible to BPL
concentration than either poliomyelitis or adenoviruses, this is the converse to that
found with formalin method for virus vaccine preparations."'" As has been reported
from this laboratory, BPL has greater virucidal potency than formalin" and BPL
combined with ultraviolet irradiation has synergistic virucidal effectivities' with antigenic potency equivalent to live vaccines compared in parallel tests. Therefore, the
use of BPL is a logical suggestion to the SV 40 problem in virus vaccine production.
In addition, the results showed the penetrability of BPL into infected cells with
inactivation of SV 40.
Of further interest is the fact that SV 40 is an oncogenic agent. These results
suggest a wider field of usefulness for sterilization with BPL. Merely evaluating
468
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the inactivation of SV 40 in tissue culture is not conclusive evidence that the oncogenic
properties have been destroyed. Therefore, such inactivated material must be evaluated
in suckling hamsters. These results are

forthcoming in subsequent publications.

SUMMARY

1.

Beta-propiolactone was found to inactivate the simian virus 40
tissue culture fluid and

infected cell suspensions at

0. 16 per cent and 0.35 per cent (wt/vol)
2.

the

(SV 40)

in

concentrations of

respectively.

These tests were evaluated in continuous kidney cell cultures of Cercopethecus
aethiops (BS-C-1).

3.

The present status of the SV 40 problem in virus vaccine production

was

reviewed, and the value of BPL in these problems was discussed.
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